Acticor Biotech SAS
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Pha… Read more
Market Cap & Net Worth: Acticor Biotech SAS (ALACT)
Acticor Biotech SAS (PA:ALACT) has a market capitalization of $3.98 Million (€3.88 Million) as of March 19, 2026. Listed on the PA stock exchange, this France-based company holds position #34067 globally and #401 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Acticor Biotech SAS's stock price €0.25 by its total outstanding shares 15510100 (15.51 Million).
Acticor Biotech SAS Market Cap History: 2021 to 2025
Acticor Biotech SAS's market capitalization history from 2021 to 2025. Data shows change from $72.92 Million to $3.98 Million (-63.18% CAGR).
Acticor Biotech SAS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Acticor Biotech SAS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ALACT by Market Capitalization
Companies near Acticor Biotech SAS in the global market cap rankings as of March 19, 2026.
Key companies related to Acticor Biotech SAS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Acticor Biotech SAS Historical Marketcap From 2021 to 2025
Between 2021 and today, Acticor Biotech SAS's market cap moved from $72.92 Million to $ 3.98 Million, with a yearly change of -63.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €3.98 Million | 0.00% |
| 2024 | €3.98 Million | -91.38% |
| 2023 | €46.17 Million | -58.92% |
| 2022 | €112.40 Million | +54.15% |
| 2021 | €72.92 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 4th, 2026 the market cap of Acticor Biotech SAS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.98 Million USD |
| MoneyControl | $3.98 Million USD |
| MarketWatch | $3.98 Million USD |
| marketcap.company | $3.98 Million USD |
| Reuters | $3.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.